Creabilis hires chief medical officer
Dr David Roblin joins the firm after holding leading roles at Pfizer and Bayer
Roblin has gained extensive experience in the pharmaceutical industry in a career spanning more than 15 years. He has held leadership roles at Pfizer and Bayer across a range of therapy areas in research, development and commercial roles.
At Pfizer, Roblin was most recently senior vice president, head of research and site head for European r&d. Before this, he was head of anti-infectives at Bayer Medical Affairs.
In addition Roblin has chaired the research director’s group of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and was a co-founder of the Innovative Medicines Initiative, a US$2bn public-private partnership with the European Commission.
You may also like
Sustainability
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security